Arcturus Therapeutics Holdings Inc. (ARCT) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Arcturus Therapeutics Holdings Inc.
Address
10628 Science Center Drive
San Diego, CA 92121
United States of America (the)
Phone
858 900 2660
Website
Sector
Healthcare
Industry
Biotechnology
Employees
174
First IPO Date
May 22, 2013
Key Executives
| Name | Title | Pay | Year Born |
| Joseph E. Payne | Founder, President, Chief Executive Officer & Director | 750,000 | 1972 |
| Joseph Roberts | Principal Accounting Officer & Controller | 219,580 | 1983 |
| Lance Kurata | Chief Legal Officer | 540,000 | N/A |
| Padmanabh Chivukula | Founder, Chief Scientific Officer, Chief Operating Officer & Secretary | 572,000 | 1979 |
| Alan H. Cohen FAAAAI FAAP FACAAI FCCP | Chief Medical Officer | 0 | 1961 |
| Ye Zhang | Chief Regulatory & Quality Assurance Officer | 0 | N/A |
| Kevin T. Skol | Chief Business Officer | 0 | N/A |
| Dennis Mulroy | Chief Financial Officer | 0 | 1955 |
| Igor Smolenov | Chief Development Officer | 0 | N/A |
| Natash O. Bowman | Chief Human Resources Officer | 0 | N/A |
| Neda Safarzadeh | Vice President and Head of IR/PR & Marketing | 0 | N/A |
Description
Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on RNA-based medicines, developing a pipeline of vaccines for infectious diseases alongside treatments for rare liver and respiratory conditions across the United States. Its notable development programs encompass LUNAR-OTC, designed for ornithine transcarbamylase (OTC) deficiency, and LUNAR-CF, targeting cystic fibrosis lung disease caused by specific CFTR gene mutations. The company also advances vaccine initiatives such as LUNAR-COV19 and LUNAR-FLU. Arcturus has cultivated a range of strategic collaborations, including partnerships with Vinbiocare Biotechnology Joint Stock Company for manufacturing COVID-19 vaccines; Janssen Pharmaceuticals, Inc., to create nucleic acid-based therapies for hepatitis B virus; Ultragenyx Pharmaceutical, Inc., for developing mRNA therapeutics aimed at rare disease targets; CureVac AG, to progress mRNA therapeutic and vaccine candidates across various indications; the Singapore Economic Development Board and Duke-NUS Medical School, specifically for the LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc., focused on discovering siRNA medicines for non-alcoholic steatohepatitis (NASH). Founded in 2013, Arcturus Therapeutics maintains its corporate headquarters in San Diego, California.
